Senior Management

Simon Wilkinson

Managing Director and CEO

Simon has been the Managing Director and Chief Executive Officer of Innate Immunotherapeutics since 2004. He has been a shareholder in the Company since its formation in 2000. Simon has overseen Innate's transition from being a public unlisted New Zealand company trialling a passive immunotherapeutic drug candidate for HIV to being a listed Australian company focused on addressing the significant and unmet need in progressive multiple sclerosis. Prior to his 15 years involvement in biotech, Simon spent 20 years in finance, banking and business management after training as an officer in the Royal New Zealand Navy.

Mark Devlin B. Sc. (Hons) PhD GradD Drug Dev

Chief Scientific Advisor

After obtaining a PhD in Pharmacology from the University of Melbourne, Mark has worked in a variety of roles focused on preclinical drug discovery and development in a number of therapeutic areas including, pain, inflammation, autoimmune disease and oncology. Mark led the biology and later the project that delivered AMP-945 and AMP-886 and has a deep knowledge of the assets.

Mark is on the Scientific Advisory Committee to the Target and Drug Discovery Platform at the Australian National University, is a Laboratory Head at the Peter MacCallum Cancer Centre, Director of Translational Cancer Biology for the CRC for Cancer Therapeutics (CTx) and is currently completing an MBA at the Melbourne Business School.

Jeff Carter

Chief Financial Officer

Mr Carter has more than 30 years of expertise in professional accounting, investment banking, corporate finance and commercial / strategic planning roles. He has served as a member of the board on a USA based company. He was the chief financial officer of the company until it’s move to the USA at the end of 2009. Since the beginning of 2000 he has served as chief financial officer and company secretary of various publicly listed healthcare companies. Prior to his move into the healthcare sector he also held senior positions with Coca Cola, Santos, Canadian Imperial Bank of Commerce and Touche Ross.